Jonathan A. Nowak: KRAS G12C mutations are predictive of response in CRCs

Jonathan A. Nowak, Molecular and Gastrointestinal Pathologist at Brigham and Women’s Hospital and the Dana-Farber Cancer Institute, shared the following on X:

“KRAS G12C mutations occur in approximately 3-4% of CRCs and are predictive of response to combo EGFR and KRAS G12C inhibition. To characterize unique features of G12C-mutant CRC, we analyzed 1,347 CRCs in the Harvard NHS/HPFS cohorts. Read more.”

Clinicopathological, molecular, and prognostic features of colorectal carcinomas with KRAS c.34G>T (p.G12C) mutation

Authors: Satoko Ugai, Qian Yao, Yasutoshi Takashima, Yuxue Zhong, Kosuke Matsuda, Hidetaka Kawamura, Yu Imamura, Kazuo Okadome, Kosuke Mima, Kota Arima, Keisuke Kosumi, Mingyang Song, Jeffrey A. Meyerhardt, Marios Giannakis, Jonathan A. Nowak, Tomotaka Ugai, Shuji Ogino.

Source: Jonathan A. Nowak/X